509 related articles for article (PubMed ID: 33925139)
1. Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
Peeters STH; Van Limbergen EJ; Hendriks LEL; De Ruysscher D
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925139
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
3. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population.
Jongbloed M; Bartolomeo V; Steens M; Dursun S; van de Lisdonk T; De Ruysscher DKM; Hendriks LEL
Eur J Cancer; 2023 Sep; 190():112947. PubMed ID: 37451182
[TBL] [Abstract][Full Text] [Related]
5. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
6. Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Billing DL; Rimner A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830925
[TBL] [Abstract][Full Text] [Related]
7. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
8. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.
Remon J; Menis J; Levy A; De Ruysscher DKM; Hendriks LEL
Transl Lung Cancer Res; 2021 Jul; 10(7):3486-3502. PubMed ID: 34430382
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
[TBL] [Abstract][Full Text] [Related]
10. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.
Zayed S; Louie AV; Breadner DA; Palma DA; Correa RJM
Ther Adv Med Oncol; 2023; 15():17588359231183668. PubMed ID: 37435562
[TBL] [Abstract][Full Text] [Related]
11. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No HJ; Raja N; Von Eyben R; Das M; Roy M; Myall N; Neal J; Wakelee H; Chin A; Diehn M; Loo BW; Chang DT; Pollom EL; Vitzthum LK
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):603-610. PubMed ID: 35654305
[TBL] [Abstract][Full Text] [Related]
13. The current state of oligometastatic and oligoprogressive non-small cell lung cancer.
Tumati V; Iyengar P
J Thorac Dis; 2018 Aug; 10(Suppl 21):S2537-S2544. PubMed ID: 30206497
[TBL] [Abstract][Full Text] [Related]
14. Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
Suh YG; Cho J
Radiat Oncol J; 2019 Sep; 37(3):149-155. PubMed ID: 31591862
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
17. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.
Tjong MC; Louie AV; Iyengar P; Solomon BJ; Palma DA; Siva S
Transl Lung Cancer Res; 2021 Jul; 10(7):3446-3456. PubMed ID: 34430379
[TBL] [Abstract][Full Text] [Related]
18. Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Santos PMG; Li X; Gomez DR
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010969
[TBL] [Abstract][Full Text] [Related]
19. Treatment Strategies for Oligometastatic Breast Cancer.
Nesbit EG; Donnelly ED; Strauss JB
Curr Treat Options Oncol; 2021 Aug; 22(10):94. PubMed ID: 34426881
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
Ning MS; Gomez DR; Heymach JV; Swisher SG
Transl Lung Cancer Res; 2019 Feb; 8(1):97-106. PubMed ID: 30788239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]